Steward Partners Investment Advisory LLC acquired a new position in shares of Baxter International Inc (NYSE:BAX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,798 shares of the medical instruments supplier’s stock, valued at approximately $175,000.

A number of other large investors also recently bought and sold shares of the business. Toronto Dominion Bank raised its position in shares of Baxter International by 8.6% in the third quarter. Toronto Dominion Bank now owns 212,015 shares of the medical instruments supplier’s stock valued at $13,304,000 after buying an additional 16,835 shares during the last quarter. Johnson Financial Group Inc. raised its position in shares of Baxter International by 15.5% in the third quarter. Johnson Financial Group Inc. now owns 21,038 shares of the medical instruments supplier’s stock valued at $1,320,000 after buying an additional 2,825 shares during the last quarter. Bahl & Gaynor Inc. raised its position in shares of Baxter International by 24.8% in the second quarter. Bahl & Gaynor Inc. now owns 20,940 shares of the medical instruments supplier’s stock valued at $928,000 after buying an additional 4,162 shares during the last quarter. Veritas Asset Management LLP raised its position in shares of Baxter International by 2.3% in the second quarter. Veritas Asset Management LLP now owns 10,179,102 shares of the medical instruments supplier’s stock valued at $616,243,000 after buying an additional 227,343 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Baxter International by 35.8% in the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock valued at $88,669,000 after buying an additional 372,500 shares during the last quarter. Institutional investors own 83.75% of the company’s stock.

Shares of Baxter International Inc (NYSE:BAX) opened at $65.29 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International Inc has a 1-year low of $43.81 and a 1-year high of $66.18. The stock has a market cap of $35,659.24, a PE ratio of 27.05, a P/E/G ratio of 2.19 and a beta of 0.69.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. The firm had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. Baxter International’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share. research analysts expect that Baxter International Inc will post 2.43 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is presently 34.41%.

A number of equities research analysts have recently commented on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a research report on Tuesday, October 24th. BMO Capital Markets reissued a “buy” rating and issued a $70.00 price objective on shares of Baxter International in a report on Friday, October 13th. Morgan Stanley upped their price objective on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a report on Thursday, October 26th. Bank of America reissued a “hold” rating on shares of Baxter International in a report on Wednesday, November 22nd. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $66.00 price objective on shares of Baxter International in a report on Wednesday, November 22nd. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $67.46.

In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the transaction, the senior vice president now owns 124,609 shares of the company’s stock, valued at $8,130,737.25. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $64.23, for a total transaction of $321,150,000.00. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Steward Partners Investment Advisory LLC Takes $175,000 Position in Baxter International Inc (BAX)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/steward-partners-investment-advisory-llc-takes-175000-position-in-baxter-international-inc-bax/1775581.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.